A meta-analysis of six double-blinded clinical trials was undertaken to identify risk factors associated with bacteriologic outcome in 3,108 women with acute cystitis. Eleven antibiotic regimens were used, including ciprofloxacin, ofloxacin, norfloxacin, trimethoprim-sulfamethoxazole, and nitrofurantoin. Entry criteria for all studies were identical. Among 2,409 patients who were defined to be valid for efficacy analysis, pathogens included Escherichia coli (78.6%), Staphylococcus saprophyticus (4.4%), Klebsiella pneumoniae (4.3%), Proteus mirabilis (3.7%), and "other" (9%). Causative bacteria were eradicated at the end of treatment in 93% of patients. The following parameters were associated with successful bacteriologic outcome: not using a diaphragm (P ‫؍‬ .0041), treatment for 3 days (P ‫؍‬ .0043), pathogen not "other" (P ‫؍‬ .0043), symptom duration of <2 days (P ‫؍‬ .0096), and African American race (P ‫؍‬ .0147). K. pneumoniae (P ‫؍‬ .0496) and "other" pathogens (P ‫؍‬ .0018) were associated with increased probability of bacteriologic treatment failure. The presence of pyuria (10 WBCs per high-power field) did not correlate with outcome and was inversely correlated with the finding of 10 5 bacterial colony-forming units per mL of urine (P < .001). This large database identifies new parameters associated with treatment outcomes of acute cystitis and calls into question current clinical trial guidelines.
Uncomplicated acute cystitis is a frequently reported infection in women [1] . Diagnosis is usually based on clinical symptoms and the demonstration of significant bacteriuria as originally defined by Kass in 1957 (10 5 cfu of bacteria/mL in a midstream urine sample) [2, 3] . More recent studies have found lower colony counts of bacteria, even of gram-positive bacteria such as Staphylococcus saprophyticus, to correlate well with clinical symptoms [4] . Revised criteria for significant bacteriuria were proposed by Stamm and colleagues [2, 5] to be 10 2 cfu of coliform organisms/mL of urine in combination with symptoms and pyuria (Ͼ5 leukocytes/high-power field [hpf] in a centrifuged urine sample or Ͼ10 leukocytes/mm 3 in an uncentrifuged sample).
More recently, microbiological criteria for the diagnosis of urinary tract infections have been defined by the Infectious Diseases Society of America (IDSA) for enrollment of patients into clinical trials; treatment failure has also been defined [6] . Specifically, IDSA recommends using a colony count of 10 3 cfu/mL to define significant bacteriuria when a single uropathogen (i.e., Enterobacteriaceae, enterococci, or S. saprophyticus) is recovered in a voided urine specimen from a female patient. In addition, the finding of 10 leukocytes/mm 3 in uncentrifuged urine is suggested as further evidence of a urinary tract infection, assuming that a rigorous technique for quantifying pyuria is used. Microbiological treatment failure is defined as culturing 10 3 cfu/mL of a uropathogen from a midstream urine specimen at any time up to and including the final follow-up visit.
The management of acute cystitis in women has evolved during the last decade from traditional 7-to 14-day therapy to short-course regimens of 1-3 days [7] [8] [9] . In addition to bacteriologic and clinical efficacy, other inherent benefits of shortcourse therapy include less development of antimicrobial resistance in the periurethral and rectal flora, improved compliance, fewer adverse reactions, and potential cost savings. Prospective studies have demonstrated the efficacy of 1-to 3-day courses of antimicrobial treatment for uncomplicated cystitis. Trimethoprim-sulfamethoxazole (TMP-SMZ) was found to be efficacious treatment in single-dose, 3-day, or longer-duration regimens [7, 8] . A 3-day course of therapy with ciprofloxacin, even at a lower daily dose, appears to be superior to single-dose therapy in women with acute cystitis [9] . Treatment regimens with ␤-lactam antibiotics given for 3 days have been associated with fewer relapses than are seen with single-dose regimens of ␤-lactams [7, 8] .
From 1989 to 1993, Bayer conducted clinical trials examining various regimens of ciprofloxacin treatment for acute, symptomatic, uncomplicated urinary tract infections in women. The purpose of these trials was to identify an appropriate minimum effective dose of ciprofloxacin for the treatment of acute cystitis. The results of the first five trials have been published [9 -11] . Because all of these clinical trials were conducted by use of nearly identical entry criteria, data collection methods, and criteria for evaluation, a meta-analysis was undertaken with two objectives: to identify demographic, clinical, and treatment parameters influencing outcome in patients with acute cystitis and to evaluate the validity of criteria proposed in published clinical trial guidelines (i.e., colony counts and pyuria) [6] . Importantly, the purpose of this metaanalysis was not to determine the effects of specific antibiotics (quinolone vs. nonquinolone) on the prediction of treatment outcome. Rather, this meta-analysis was undertaken to clarify the differences in U.S. Food and Drug Administration (FDA) and IDSA guidelines for the evaluation of antibiotics in the treatment of urinary tract infections [6] . Specifically, the FDA guidelines, in contrast to IDSA guidelines [6] , exclude patients with acute symptoms and pyuria from the primary efficacy analysis if colony counts are Ͻ10 5 cfu/mL [6] . In addition, both the FDA and IDSA guidelines require that pyuria, as defined by Kass [3] , be present before treatment for patients to be included in the study analysis. By analyzing this large database of trials conducted under the existing FDA and IDSA guidelines, we are able to assess the validity of the recommended colony count and pyuria measures.
Patients and Methods
Study design and antimicrobial therapy. Six multicenter, prospective, randomized, double-blind trials were conducted between 1989 and 1993 to determine the minimum effective dose of ciprofloxacin for the treatment of acute cystitis in women. The following treatment regimens were used in the six studies (two or three treatment groups per study): ciprofloxacin at 100 mg twice daily for 3 days (three trials), ciprofloxacin at 250 mg twice daily for 7 days (three trials), ciprofloxacin at a 500-mg single dose (two trials), ciprofloxacin at 500 mg once daily for 3 days (one trial), ciprofloxacin at 500 mg once daily for 5 days (one trial), ofloxacin at 200 mg twice daily for 3 days (one trial), nitrofurantoin at 100 mg twice daily for 7 days (one trial), TMP-SMZ at 160 and 800 mg, respectively, twice daily for 3 days (one trial), and TMP-SMZ at 160 and 800 mg, respectively, twice daily for 7 days (one trial). Because of the differences in treatment durations and number of daily doses, all studies maintained blinding by use of placebo administration.
Patient population. The entry criteria for each of the six studies were similar. Premenopausal adult women (Ͼ17 years of age) with a primary diagnosis of acute, symptomatic, uncomplicated urinary tract infection were enrolled. Enrolled patients had positive results of culture from a clean-catch midstream urine specimen within 48 hours before treatment (i.e., a single organism with a colony count of 10 3 cfu/mL of urine) accompanied by signs and symptoms such as pyuria, dysuria, hematuria, or urinary frequency that were of 7 days' duration. Pyuria was defined as a positive result of leukocyte esterase dipstick testing (in two of six studies) or Ͼ10 WBCs/hpf by hemocytometer (four of six studies). At study entry, each patient was questioned as to the duration of her symptoms (days), history of a previous urinary tract infection in the last year, frequency of sexual intercourse per month, number of sex partners during the last year, and contraceptive methods. Exclusion criteria included allergy to any study drug, lack of symptoms, pregnancy, lactation, suspected bacteremia, clinically significant lower or upper urinary tract obstruction, neurogenic bladder, indwelling urinary catheter during the course of therapy, or renal insufficiency (estimated creatinine clearance of Ͻ30 mL/[min ⅐ 1.73 m 2 ]). Each patient was enrolled only once. Written informed consent was obtained from all participants.
Bacteriologic evaluation of voided urine was done at the end of treatment (defined as 4 -9 days after the last dose) and at follow-up (4 -6 weeks after the last dose).
Efficacy evaluation. Patients were considered valid for efficacy if they met entry criteria as described above, had isolation of a single pre-therapy urinary pathogen with a colony count of 10 3 cfu/mL from a midstream clean-catch urine specimen, and had had a follow-up culture of a urine specimen. Patients were excluded from this population if urine cultures were not obtained at the required time after therapy (see below). In this meta-analysis, patients were not excluded solely because of noncompliance with treatment regimens. Patients whose study drug was discontinued prematurely because of an adverse event were included in the efficacy analysis if they satisfied the aforementioned criteria and had received a minimum of 3 days (one study) or 7 days (five studies) of therapy.
Two response variables were considered in this analysis. Bacteriologic responses at the end of therapy were defined as eradication (causative organism absent 4 -9 days after completion of all study medication including placebo), failure (persistence of causative organism at colony counts of 10 3 cfu/mL at any time after the first 2 days of therapy), or superinfection (a new organism present at a count of 10 3 cfu/mL at any time during therapy or up to 9 days after completion of therapy). Bacteriologic responses at the 4-to 6-week follow-up visit were defined as success (continued eradication of the causative organism) or failure (end-of-therapy failure, relapse with the original causative pathogen, or reinfection with new pathogens).
Statistical analysis. A linear logistic regression model was fit to the two binary response variables by the method of maximum likelihood. Stepwise selection was used to identify the prognostic factors for bacteriologic success from a variety of demographic, clinical, and treatment variables. The significance level for entry into and remaining in the model was P .05.
Independent patient variables included in the database were analyzed by logistic regression to determine whether any could be considered prognostic for bacteriologic outcome. They included demographic and sexual history (age, weight, race, birth control method, frequency of sexual intercourse per month, number of sex partners in previous 12 months), clinical parameters (history of urinary tract infection in previous 12 months, duration of symptoms, general health status), laboratory parameters (WBC count of Ͼ10 cells/hpf, bacterial colony count of 10 3 cfu/mL, genus and species of causative organisms), duration of treatment (single dose, 3-day, 5-day, and 7-day), antibiotic (quinolone vs. nonquinolone), intercurrent illness, and concomitant medication.
Results
Study population. Of the 3,108 women enrolled, 2,409 (77.5%) were valid for efficacy evaluation. As determined by following published guidelines, the primary reasons for exclusion from the efficacy analysis included no organism isolated before therapy or colony counts of Ͻ10 3 cfu/mL (n ϭ 590), isolation of multiple pathogens (n ϭ 70), and missing or indeterminate bacteriologic response (n ϭ 39). The most common combination of multiple pathogens isolated included Escherichia coli plus Enterococcus species, E. coli plus Proteus mirabilis, or two strains of E. coli; only 4 women had isolation of E. coli plus S. saprophyticus.
The baseline demographics and medical characteristics for women enrolled in the six multicenter study trials who were valid for efficacy evaluation are summarized in table 1. There were no significant differences among the six studies with respect to race, age, health status, previous use of antimicrobials, or presence of accompanying diseases. The mean age for the 2,409 patients valid for efficacy analysis was 32 years, and ϳ84% were Caucasian. Sixteen percent of patients reported a history of previous urinary tract infection within the last year. In addition, 541 patients valid for efficacy evaluation (22%) were Ͼ40 years old, of which 91 (17%) reported a previous urinary tract infection. The median duration of symptoms for the current urinary tract infection episode was 3 days for patients in all six studies. Pyuria (Ͼ10 WBCs/hpf) and high bacterial colony counts (10 5 cfu/mL) were reported in 68% and 85%, respectively, of patients valid for efficacy evaluation. Of note, one center reported all colony counts as 10 4 cfu/mL. Because we could not determine which patients from this site had counts of 10 4 cfu/mL vs. 10 5 cfu/mL, all analyses involving colony counts excluded the 222 patients from this site. The majority of patients valid for efficacy evaluation received a quinolone antimicrobial (75%). Overall, most women (93%) were treated for 3 days.
Bacteriologic response. E. coli represented the most commonly isolated pathogen (78.2% [1, 884] Eradication rates were uniformly high among the five treatment agents, regardless of treatment dose and duration. Specifically, eradication of the original causative pathogen at the end of therapy occurred in 1,003 ciprofloxacin-treated subjects (92%), 185 ofloxacin-treated subjects (96%), 135 norfloxacintreated subjects (94%), 126 nitrofurantoin-treated subjects (89%), and 124 TMP-SMZ-treated subjects (91%). Colony count was not predictive of end-of-therapy eradication rate: for subjects with counts of 10 3 to Ͻ10 5 cfu/mL the eradication rate was 94% (308 of 328) and for subjects with counts of 10 5 cfu/mL it was 92% (1,701 of 1,843). Eradication rates at the end of therapy within each antimicrobial group were not statistically different when stratified by moderate (10 3 -10 4 cfu/mL) or high (10 5 cfu/mL) bacterial colony counts (table  2) . Eradication rates stratified by WBC count in urine before therapy, as determined by using either the leukocyte esterase test or hemocytometer, also failed to demonstrate any signifi- Eradication rates by treatment duration and colony count at the end of therapy failed to reveal any clinically useful associations. Unexpectedly, eradication with single-dose treatment appeared to be more likely with bacterial colony counts of 10 5 cfu/mL (table 2) . For subjects receiving 3-day therapy with ciprofloxacin, eradication rates were 95% (n ϭ 97) for those with counts of 10 3 -10 4 cfu/mL and 91% (n ϭ 529) for those with counts of 10 5 cfu/mL (P ϭ .20). Single-dose therapy was also associated with a relatively higher failure rate than was treatment given for 3 days. In particular, 17 (10%) of 170 women who received single-dose ciprofloxacin had bacteriologic failure at the end of therapy. Furthermore, among 114 patients treated with single-dose ciprofloxacin who had treatment success at the end of therapy and had follow-up testing, 13 patients (11%) had "late" failure (i.e., relapses or reinfections).
Prognostic factors for bacteriologic response. Selected baseline and treatment characteristics, including patient age, race, history of a previous urinary tract infection, birth control method, species of organisms isolated before treatment, antimicrobial agent, and treatment duration, were correlated with bacteriologic eradication at the end of therapy and at follow-up. Logistic regression analysis using the selected characteristics for the entire pool of patients valid for efficacy revealed that successful bacteriologic outcome at the end of therapy was correlated with not using a diaphragm (OR ϭ 3.4; P ϭ .004), treatment for 3 days (OR ϭ 6.2; P ϭ .004), pathogen not "other" (OR ϭ 1.9; P ϭ .004), duration of symptoms of Ͻ2 days (OR ϭ 1.5; P ϭ .010), and African American race (OR ϭ 2.6; P ϭ .015) (table 3). There was no significant correlation between the occurrence of a urinary tract infection in the previous year and bacteriologic outcome. At follow-up, quinolone therapy was associated with increased probability of eradication (OR ϭ 1.6; P ϭ .004), while "other" pathogen (OR ϭ 1.8; P ϭ .002) and K. pneumoniae (OR ϭ 1.7; P ϭ .050) were associated with increased probability of bacteriologic failure (table 3) .
Pyuria and colony count. The association of pyuria (Ͼ10 WBCs/hpf) at study entry with the pathogen identified before therapy was examined by use of either the leukocyte esterase test or hemocytometer count. Notably, 67% of patients had pyuria determined objectively by use of a hemocytometer. Overall, pyuria was identified in 54%-71% of subjects valid for efficacy analysis. For subjects with E. coli isolated before therapy, pyuria was found in 70% of cases, compared with 61% for all other organisms.
Pyuria at study entry was found to be inversely correlated with moderate to high colony counts. Among 330 subjects with colony counts of 10 3 to Ͻ10 5 cfu/mL, 77% had pyuria, compared with 62% of 1,845 subjects with colony counts of 10 5 cfu/mL (P Ͻ .001). This relationship is consistent among women with E. coli as the infecting pathogen: 77% with colony NOTE. Odds ratios of Ͼ1 are prognostic for bacteriologic success and those of Ͻ1 are prognostic for bacteriologic failure. ND ϭ not determined because these variables were not found to be statistically significant by logistic regression analysis. (8) NOTE. Pyuria was estimated either by use of the leukocyte esterase test or by hemocytometer count. Data are no. with characteristic (%).
* n ϭ 1,616; duration of symptoms data were not available for two patients.
counts of Ͻ10 5 cfu/mL compared with 65% with counts of 10 5 cfu/mL had pyuria (table 4) . Furthermore, the presence of pyuria was not associated with duration of symptoms (table  5) . To the contrary, duration of symptoms was somewhat predictive of colony count (i.e., subjects with symptoms for 2 days were more likely to have a colony count of 10 5 cfu/mL; P Ͻ .001) (table 6).
Discussion
Although short-course therapy-both single-dose and 3-day regimens-has been evaluated and shown to be effective for acute uncomplicated urinary tract infection in women [7, 8] , single doses of fluoroquinolones have been reported to be less effective, both bacteriologically and clinically, than treatment of at least 3 days' duration [9 -13] . This large-sample metaanalysis also confirmed that single-dose treatment with a quinolone is less effective than 3-to 7-day therapy. Data for single-dose grepafloxacin and trovafloxacin for the treatment of acute cystitis are lacking. Currently, only fosfomycin is approved as a single-dose treatment for acute cystitis [14] . In addition, this meta-analysis demonstrated that fluoroquinolones had bacteriologic efficacy superior to that of nitrofurantoin and TMP-SMZ in preventing relapses and reinfections. Importantly, the superiority of fluoroquinolones over nonquinolone antibiotics is probably a conservative estimate, because pathogens resistant to either study drug were excluded from the efficacy analysis. Previous trials have shown that quinolones and TMP-SMZ are more effective than ␤-lactams in completely eradicating bacteriuria [4, [15] [16] [17] . The greater efficacy of quinolones and TMP-SMZ has been explained by higher and more persistent inhibitory concentrations in the urine. Reduction in uropathogens in the bowel and the perineum may also be responsible [18, 19] .
It is important to emphasize that this meta-analysis was based on studies completed in the early 1990s or before. Since that time, increasing prevalence of TMP-SMZ resistance among uropathogens, especially E. coli, has been reported both in the United States and abroad [20 -25] . Furthermore, Talan et al. demonstrated a significant association between in vitro resistance of TMP-SMZ against E. coli and clinical and bacteriologic failure in TMP-SMZ-treated women with acute uncomplicated pyelonephritis [25] . In the same study, all ciprofloxacin-treated women infected with TMP-SMZ-resistant E. coli were clinically and bacteriologically cured. Accordingly, reduced susceptibility of E. coli to TMP-SMZ, as high as 60% in some countries, suggests that alternative empiric antimicrobials be considered in geographic regions with a high prevalence of resistance [20 -25] .
The meta-analysis described herein includes data from Ͼ2,400 women for whom bacteriologic efficacy could be evaluated by conventional urine cultures and among whom various population risk factors could be examined with adequate statistical power. Consistent with the other reports, age, the duration of symptoms, and the use of certain types of contraception were associated with a less favorable outcome [26, 27] . In this meta-analysis, women with prolonged symptoms (2 days) were more likely to have a higher colony count, thereby suggesting the need for a longer treatment course. The less frequently isolated organisms (those considered together as "other" and K. pneumoniae) were also associated with a less favorable outcome. S. saprophyticus responded better in this meta-analysis than was reported in a study with norfloxacin [13] . In addition, African American women were more likely to have a favorable outcome. Since our study population did not include clinics serving predominantly African American communities but rather included the cross-sectional racial distribution seen in college and university populations, our finding of higher cure rates in African American women needs to be confirmed in a larger well-designed trial.
The studies included in this meta-analysis were all executed with the intention of future data submission to the U.S. FDA and other regulatory bodies, and therefore they were conducted according to published guidelines for clinical trials for evaluating antimicrobial treatment of acute uncomplicated urinary tract infections [6] . Nevertheless, there remains controversy over the inclusion of symptomatic patients with colony counts of Ͻ10 5 cfu/mL, because patients with higher colony counts, 10 5 cfu/mL, are presumed to be more difficult to treat [28] . For the fluoroquinolones, there appears to be no justification for this assumption. However, with nitrofurantoin, there was a suggestion of lower efficacy in patients with higher colony counts.
More important for the conduct of clinical trials was the failure of microscopically documented pyuria to correlate with significant bacteriuria. All of our patients were symptomatic, and all patients valid for efficacy determination had a single uropathogen isolated, yet only 68% had documented pyuria. However, one limitation of this meta-analysis was the use of two different methods to determine degree of pyuria (leukocyte esterase test or hemocytometer count). The leukocyte esterase test, a subjective measure of pyuria, was used in only two of the six studies. The more objective method (hemocytometer count) was used for the majority of patients valid for efficacy determination. The apparent lack of association between pyuria and significant bacteriuria was observed with both methods. There was a stronger relationship between the presence of E. coli and pyuria (70%) than between all other organisms and pyuria (59%). The findings of this meta-analysis are very consistent with a recent multicenter clinical trial analysis done in Sweden, in which the definition of significant bacteriuria was explored [29] . In the Swedish trial, 29% of symptomatic female patients with significant bacteriuria were found not to have significant pyuria [29] . The data establishing the correlation between pyuria and significant bacteriuria were discussed by Stamm [5] : he reported that Ͼ96% of symptomatic women with significant bacteriuria and uncomplicated urinary tract infection had WBC counts in urine of 10 leukocytes/mm 3 [5] . His own research analyzed colony counts in acute symptomatic women; however, the study used specimen collection methods not consistent with clinical practice [2] . The Stamm study used techniques for concentrating urine, and "quantitative leukocyte counts were performed immediately upon obtaining each patient's mid-stream urine specimen." Since Stamm's study used optimal conditions for processing the urine, the results do not reflect the clinical setting in which large multicenter clinical trials are conducted. It is known that a delay in specimen handling, particularly at room temperature, may affect the chemical and cellular characteristics of urine [30, 31] . We conclude that pyuria should not be an independent criterion for patient validity in clinical trials, although the data should be collected to provide a better description of the patient population. In clinical practice, the lack of significant pyuria findings should be interpreted with other diagnostic criteria.
As future clinical trials become harmonized as a result of regulatory guidelines, additional meta-analyses may provide more information on the clinical and demographic characteristics of patients enrolled in clinical trials. It is important to identify those factors that truly influence treatment outcome so that they may be incorporated in future study designs and analyses. These descriptive characteristics are also important so that practicing physicians can appropriately interpret the clinical trial data when considering treatment for their own patients.
In conclusion, quinolones are more effective than nitrofurantoin and TMP-SMZ in preventing recurrence of bacteriuria. Single-dose ciprofloxacin was less effective than treatment with a 3-day short course of therapy for acute cystitis in women. Certain patient characteristics (older age, symptoms lasting for Ͼ2 days, diaphragm use, isolation of K. pneumoniae) appear to influence bacteriologic outcome, suggesting that a more prolonged treatment course (5-7 days) may be appropriate in this population of women. This meta-analysis also submits that the finding of pyuria in urine specimens obtained before treatment is of limited clinical usefulness and its absence should not be an exclusion criterion in the conduct of clinical trials. Finally, if local resistance patterns suggest an increasing rate of TMP-SMZ resistance among E. coli, ciprofloxacin or another quinolone should be considered as empiric therapy for management of urinary tract infections.
